Association of Copresence of Pathogenic Variants Related to Amyotrophic Lateral Sclerosis and Prognosis.

Background And Objectives: Despite recent advances, it is not clear whether the various genes/genetic variants related to amyotrophic lateral sclerosis (ALS) interact in modifying patients' phenotype. The aim of this study was to determine whether the copresence of genetic variants related to ALS has interactive effects on the course of the disease.

Methods: The study population includes 1,245 patients with ALS identified through the Piemonte Register for ALS between 2007 and 2016 and not carrying superoxide dismutase type 1, TAR DNA binding protein, and fused in sarcoma pathogenic variants. Controls were 766 Italian participants age-matched, sex-matched, and geographically matched to cases. We considered Unc-13 homolog A () (rs12608932), calmodulin binding transcription activator 1 () (rs2412208), solute carrier family 11 member 2 () (rs407135), and zinc finger protein 512B () (rs2275294) variants, as well as ataxin-2 () polyQ intermediate repeats (≥31) and chromosome 9 open reading frame 72 () GGGGCC intronic expansions (≥30).

Results: The median survival time of the whole cohort was 2.67 years (interquartile range [IQR] 1.67-5.25). In univariate analysis, only (2.51 years, IQR 1.74-3.82; = 0.016), (1.82 years, IQR 1.08-2.33; < 0.001), and (2.3 years, IQR 1.3-3.9; < 0.001) significantly reduced survival. In Cox multivariable analysis, also emerged to be independently related to survival (hazard ratio 1.13, 95% CI 1.001-1.30, = 0.048). The copresence of 2 detrimental alleles/expansions was correlated with shorter survival. In particular, the median survival of patients with and alleles was 1.67 years (1.16-3.08) compared with 2.75 years (1.67-5.26) of the patients not carrying these variants ( < 0.001); the survival of patients with alleles and intermediate polyQ repeats was 1.75 years (0.84-2.18) ( < 0.001); the survival of patients with polyQ repeats and allele was 1.33 years (0.84-1.75) ( < 0.001); the survival of patients with and allele was 1.66 years (1.41-2.16). Each pair of detrimental alleles/expansions was associated to specific clinical phenotypes.

Discussion: We showed that gene variants acting as modifiers of ALS survival or phenotype can act on their own or in unison. Overall, 54% of patients carried at least 1 detrimental common variant or repeat expansion, emphasizing the clinical impact of our findings. In addition, the identification of the interactive effects of modifier genes represents a crucial clue for explaining ALS clinical heterogeneity and should be considered when designing and interpreting clinical trials results.